Ligand-based Targeting of Disease: From Antibodies to Small Organic (Synthetic) Ligands

Modern Biopharmaceuticals: Design, Development and Optimization

Volumn 3, Issue , 2008, Pages 1271-1299

  Silacci, Michela ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Atherosclerosis; Formidable; Ligand; Stromal antigens; Thrombin

Indexed keywords

EID: 84889986358     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527620982.ch52     Document Type: Chapter

References (186)

1. Maeda, H., Fang, J., Inutsuka, T., and Kitamoto, Y. (2003) Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications, Int Immunopharmacol 3, 319-328.
2. Kopecek, J., Kopeckova, P., Minko, T., Lu, Z. R., and Peterson, C. M. (2001) Water soluble polymers in tumor targeted delivery, J Control Release 74, 147-158.
3. Duncan, R. (1999) Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway, Pharm Sci Technol Today 2(11), 441-449.
4. Duncan, R. (1992) Drug-polymer conjugates: potential for improved chemotherapy, Anticancer Drugs 3, 175-210.
5. Maeda, H. (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting, Adv Enzyme Regul 41, 189-207.
6. Kohler, G., and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity, Nature 256, 495-497.
7. Steinitz, M., Klein, G., Koskimies, S., and Makel, O. (1977) EB virus-induced B lymphocyte cell lines producing specific antibody, Nature 269, 420-422.
8. Kozbor, D., and Roder, J.C. (1981) Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique, J Immunol 127, 1275-1280.
9. Kozbor, D., Roder, J. C., Chang, T. H., Steplewski, Z., and Koprowski, H. (1982) Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma, Hybridoma 1, 323-328.
10. Karpas, A., Dremucheva, A., and Czepulkowski, B.H. (2001) A human myeloma cell line suitable for the generation of human monoclonal antibodies, Proc Natl Acad Sci USA 98, 1799-1804.
11. Jones, P.T., Dear, P. H., Foote, J., Neuberger, M.S., and Winter, G. (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature 321, 522-525.
12. McCafferty, J., Griffiths, A. D., Winter, G., and Chiswell, D.J. (1990) Phage antibodies: filamentous phage displaying antibody variable domains, Nature 348, 552-554.
13. Viti, F., Nilsson, F., Demartis, S., Huber, A., and Neri, D. (2000) Design and use of phage display libraries for the selection of antibodies and enzymes, Methods Enzymol 326, 480-505.
14. Green, L. L. (1999) Antibody engineering via genetic engineering of the mouse: Xeno-Mouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies, J Immunol Methods 231, 11-23.
15. Walsh, G. (2003) Biopharmaceutical benchmarks-2003, Nat Biotechnol 21, 865-870.
16. Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H.R. (1994) Making antibodies by phage display technology, Annu Rev Immunol 12, 433-455.
17. Schier, R., Marks, J. D., Wolf, E. J., Apell, G., Wong, C., McCartney, J. E., Bookman, M.A., Huston, J. S., Houston, L. L., Weiner, L. M., and et al. (1995) In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library, Immunotechnology 1, 73-81.
18. Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., and Neri, D. (1998) Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel, J Biol Chem 273, 21769-21776.
19. Schaffitzel, C., Hanes, J., Jermutus, L., and Pluckthun, A. (1999) Ribosome display: an in vitro method for selection and evolution of antibodies from libraries, J Immunol Methods 231, 119-135.
20. Kowalski, J., Henze, M., Schuhmacher, J., Macke, H.R., Hofmann, M., and Haberkorn, U. (2003) Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors, Mol Imaging Biol 5, 42-48.
21. Ginj, M., and Maecke, H.R. (2004) Radiometallo-labeled peptides in tumor diagnosis and therapy, Met Ions Biol Syst 42, 109-142.
22. Behr, T. M., Gotthardt, M., Barth, A., and Behe, M. (2001) Imaging tumors with peptide-based radioligands, Q J Nucl Med 45, 189-200.
23. Chen, X., Park, R., Hou, Y., Khankaldyyan, V., Gonzales-Gomez, I., Tohme, M., Bading, J. R., Laug, W. E., and Conti, P. S. (2004) MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide, Eur J Nucl Med Mol Imaging 31, 1081-1089.
24. Okarvi, S. M., and al-Jammaz, I. (2003) Synthesis, radiolabelling and biological characteristics of a bombesin peptide analog as a tumor imaging agent, Anticancer Res 23, 2745-2750.
25. Felici, F., Luzzago, A., Monaci, P., Nicosia, A., Sollazzo, M., and Traboni, C. (1995) Peptide and protein display on the surface of filamentous bacteriophage, Biotechnol Annu Rev 1, 149-183.
26. Oyama, T., Sykes, K. F., Samli, K. N., Minna, J. D., Johnston, S. A., and Brown, K. C. (2003) Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents, Cancer Lett 202, 219-230.
27. Collins, J., Horn, N., Wadenback, J., and Szardenings, M. (2001) Cosmix-plexing: a novel recombinatorial approach for evolutionary selection from combinatorial libraries, J Biotechnol 74, 317-338.
28. Pasqualini, R., and Ruoslahti, E. (1996) Organ targeting in vivo using phage display peptide libraries, Nature 380, 364-366.
29. Trepel, M., Arap, W., and Pasqualini, R. (2002) In vivo phage display and vascular heterogeneity: implications for targeted medicine, Curr Opin Chem Biol 6, 399-404.
30. Arkin, M.R., and Wells, J. A. (2004) Smallmolecule inhibitors of protein-protein interactions: progressing towards the dream, Nat Rev Drug Discov 3, 301-317.
31. Mammen, M., C. S.-K., Whitesides G.M. (1998) Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. Angewandte Chemie International Edition, 2754-2794.
32. Shuker, S. B., Hajduk, P. J., Meadows, R. P., and Fesik, S.W. (1996) Discovering high-affinity ligands for proteins: SAR by NMR, Science 274, 1531-1534.
33. Ramstrom, O., and Lehn, J.M. (2002) Drug discovery by dynamic combinatorial libraries, Nat Rev Drug Discov 1, 26-36.
34. Erlanson, D.A., Lam, J.W., Wiesmann, C., Luong, T. N., Simmons, R. L., DeLano, W. L., Choong, I. C., Burdett, M.T., Flanagan, W. M., Lee, D., Gordon, E. M., and O'Brien, T. (2003) In situ assembly of enzyme inhibitors using extended tethering, Nat Biotechnol 21, 308-314.
35. Melkko, S., Scheuermann, J., Dumelin, C. E., and Neri, D. (2004) Encoded self-assembling chemical libraries, Nat Biotechnol 22, 568-574.
36. Johnson, V. G., Schlom, J., Paterson, A. J., Bennett, J., Magnani, J. L., and Colcher, D. (1986) Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3, Cancer Res 46, 850-857.
37. Nuti, M., Teramoto, Y. A., Mariani-Costantini, R., Hand, P. H., Colcher, D., and Schlom, J. (1982) A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations, Int J Cancer 29, 539-545.
38. Guadagni, F., Roselli, M., Cosimelli, M., Ferroni, P., Spila, A., Cavaliere, F., Arcuri, R., Carlini, S., Mariotti, S., Gandolfo, G.M., Casciani, C. U., Greiner, J.W., and Schlom, J. (1996) TAG-72 expression and its role in the biological evaluation of human colorectal cancer, Anticancer Res 16, 2141-2148.
39. Guadagni, F., Roselli, M., Cosimelli, M., Mannella, E., Tedesco, M., Cavaliere, F., Grassi, A., Abbolito, M.R., Greiner, J.W., and Schlom, J. (1993) TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer, Cancer 72, 2098-2106.
40. Chieng, D.C., Rodriguez-Burford, C., Talley, L. I., Sviglin, H., Stockard, C. R., Kleinberg, M.J., Barnes, M.N., Partridge, E. E., Khazaeli, M.B., and Grizzle, W. E. (2003) Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma, Hum Pathol 34, 1016-1021.
41. Gold, P., and Freedman, S. O. (1965) Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques, J Exp Med 121, 439-462.
42. Duffy, M. J. (2001) Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?, Clin Chem 47, 624-630.
43. Verhaar, M. J., Chester, K. A., Keep, P. A., Robson, L., Pedley, R. B., Boden, J. A., Hawkins, R. E., and Begent, R.H. (1995) A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma, Int J Cancer 61, 497-501.
44. Verhaar, M. J., Keep, P. A., Hawkins, R. E., Robson, L., Casey, J. L., Pedley, B., Boden, J. A., Begent, R. H., and Chester, K.A. (1996) Technetium-99m radiolabeling using a phagederived single-chain Fv with a C-terminal cysteine, J Nucl Med 37, 868-872.
45. Cooke, S. P., Pedley, R. B., Boden, R., Begent, R. H., and Chester, K.A. (2002) In vivo tumor delivery of a recombinant single chain Fv: tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein, Bioconjug Chem 13, 7-15.
46. Francis, R. J., Mather, S. J., Chester, K., Sharma, S. K., Bhatia, J., Pedley, R. B., Waibel, R., Green, A. J., and Begent, R.H. (2004) Radiolabelling of glycosylated MFE-23:CPG2 fusion protein (MFECP1) with (99m)Tc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT), Eur J Nucl Med Mol Imaging 31, 1090-1096.
47. Horoszewicz, J. S., Kawinski, E., and Murphy, G. P. (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients, Anticancer Res 7, 927-935.
48. Gong, M.C., Chang, S. S., Sadelain, M., Bander, N. H., and Heston, W. D. (1999) Prostatespecific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers, Cancer Metastasis Rev 18, 483-490.
49. Freeman, L. M., Krynyckyi, B. R., Li, Y., Korupulu, G., Saleemi, K., Haseman, M.K., and Kahn, D. (2002) The role of (111)In Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer, Q J Nucl Med 46, 131-137.
50. Rubin, I., and Yarden, Y. (2001) The basic biology of HER2, Ann Oncol 12 Suppl 1, S3-8.
51. Menard, S., Pupa, S. M., Campiglio, M., and Tagliabue, E. (2003) Biologic and therapeutic role of HER2 in cancer, Oncogene 22, 6570-6578.
52. Hung, M.C., and Lau, Y. K. (1999) Basic science of HER-2/neu: a review, Semin Oncol 26, 51-59.
53. Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., and Shepard, H.M. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy, Proc Natl Acad Sci USA 89, 4285-4289.
54. Park, J.W., Stagg, R., Lewis, G. D., Carter, P., Maneval, D., Slamon, D.J., Jaffe, H., and Shepard, H.M. (1992) Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy, Cancer Treat Res 61, 193-211.
55. Fischer, O.M., Streit, S., Hart, S., and Ullrich, A. (2003) Beyond Herceptin and Gleevec, Curr Opin Chem Biol 7, 490-495.
56. Mass, R. D. (2004) The HER receptor family: a rich target for therapeutic development, Int J Radiat Oncol Biol Phys 58, 932-940.
57. Keler, T., Graziano, R. F., Mandal, A., Wallace, P. K., Fisher, J., Guyre, P. M., Fanger, M.W., and Deo, Y.M. (1997) Bispecific antibody-dependent cellular cytotoxicity of HER2/neuoverexpressing tumor cells by Fc gamma receptor type I-expressing effector cells, Cancer Res 57, 4008-4014.
58. Riley, J. K., and Sliwkowski, M.X. (2000) CD20: a gene in search of a function, Semin Oncol 27, 17-24.
59. Krasner, C., and Joyce, R.M. (2001) Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma, Curr Pharm Biotechnol 2, 341-349.
60. Vose, J.M. (2004) Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma, Oncologist 9, 160-172.
61. Went, P.T., Lugli, A., Meier, S., Bundi, M., Mirlacher, M., Sauter, G., and Dirnhofer, S. (2004) Frequent EpCam protein expression in human carcinomas, Hum Pathol 35, 122-128.
62. Herlyn, M., Steplewski, Z., Herlyn, D., and Koprowski, H. (1979) Colorectal carcinomaspecific antigen: detection by means of monoclonal antibodies, Proc Natl Acad Sci USA 76, 1438-1442.
63. Poczatek, R. B., Myers, R. B., Manne, U., Oelschlager, D. K., Weiss, H.L., Bostwick, D.G., and Grizzle, W. E. (1999) Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia, J Urol 162, 1462-1466.
64. Ruck, P., Wichert, G., Handgretinger, R., and Kaiserling, E. (2000) Ep-CAM in malignant liver tumours, J Pathol 191, 102-103.
65. Braun, S., Hepp, F., Kentenich, C. R., Janni, W., Pantel, K., Riethmuller, G., Willgeroth, F., and Sommer, H.L. (1999) Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow, Clin Cancer Res 5, 3999-4004.
66. Punt, C. J., Nagy, A., Douillard, J.Y., Figer, A., Skovsgaard, T., Monson, J., Barone, C., Fountzilas, G., Riess, H., Moylan, E., Jones, D., Dethling, J., Colman, J., Coward, L., and Mac-Gregor, S. (2002) Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study, Lancet 360, 671-677.
67. Bischoff, J. (1995) Approaches to studying cell adhesion molecules in angiogenesis, Trends Cell Biol 5, 69-74.
68. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease, Nat Med 1, 27-31.
69. Pugh, C.W., and Ratcliffe, P. J. (2003) Regulation of angiogenesis by hypoxia: role of the HIF system, Nat Med 9, 677-684.
70. Carmeliet, P. (2003) Angiogenesis in health and disease, Nat Med 9, 653-660.
71. Gerber, H. P., and Ferrara, N. (2003) The role of VEGF in normal and neoplastic hematopoiesis, J Mol Med 81, 20-31.
72. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med 350, 2335-2342.
73. Cobleigh, M.A., Langmuir, V. K., Sledge, G.W., Miller, K. D., Haney, L., Novotny, W. F., Reimann, J. D., and Vassel, A. (2003) A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer, Semin Oncol 30, 117-124.
74. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications, N Engl J Med 285, 1182-1186.
75. Folkman, J. (1972) Anti-angiogenesis: new concept for therapy of solid tumors, Ann Surg 175, 409-416.
76. Hanahan, D. (1998) A flanking attack on cancer, Nat Med 4, 13-14.
77. Bergers, G., and Benjamin, L. E. (2003) Tumorigenesis and the angiogenic switch, Nat Rev Cancer 3, 401-410.
78. Forsythe, J. A., Jiang, B. H., Iyer, N.V., Agani, F., Leung, S.W., Koos, R. D., and Semenza, G. L. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1, Mol Cell Biol 16, 4604-4613.
79. Ivan, M., Haberberger, T., Gervasi, D. C., Michelson, K. S., Gunzler, V., Kondo, K., Yang, H., Sorokina, I., Conaway, R. C., Conaway, J. W., and Kaelin, W. G., Jr. (2002) Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor, Proc Natl Acad Sci USA 99, 13459-13464.
80. Jaakkola, P., Mole, D.R., Tian, Y. M., Wilson, M.I., Gielbert, J., Gaskell, S. J., Kriegsheim, A., Hebestreit, H.F., Mukherji, M., Schofield, C. J., Maxwell, P. H., Pugh, C.W., and Ratcliffe, P. J. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation, Science 292, 468-472.
81. Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., and Kaelin, W. G., Jr. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing, Science 292, 464-468.
82. Dibbens, J. A., Miller, D. L., Damert, A., Risau, W., Vadas, M.A., and Goodall, G. J. (1999) Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements, Mol Biol Cell 10, 907-919.
83. Tenan, M., Fulci, G., Albertoni, M., Diserens, A. C., Hamou, M.F., El Atifi-Borel, M., Feige, J. J., Pepper, M. S., and Van Meir, E.G. (2000) Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells, J Exp Med 191, 1789-1798.
84. Konerding, M.A., Fait, E., and Gaumann, A. (2001) 3D microvascular architecture of precancerous lesions and invasive carcinomas of the colon, Br J Cancer 84, 1354-1362.
85. Roberts, W. G., and Palade, G.E. (1997) Neovasculature induced by vascular endothelial growth factor is fenestrated, Cancer Res 57, 765-772.
86. Jain, R. K. (1987) Transport of molecules across tumor vasculature, Cancer Metastasis Rev 6, 559-593.
87. Hashizume, H., Baluk, P., Morikawa, S., McLean, J.W., Thurston, G., Roberge, S., Jain, R. K., and McDonald, D.M. (2000) Openings between defective endothelial cells explain tumor vessel leakiness, Am J Pathol 156, 1363-1380.
88. Ferrara, N., Hillan, K. J., Gerber, H. P., and Novotny, W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer, Nat Rev Drug Discov 3, 391-400.
89. Kerbel, R. S. (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents, BioEssays 13, 31-36.
90. Sekiguchi, K., Siri, A., Zardi, L., and Hakomori, S. (1985) Differences in domain structure between human fibronectins isolated from plasma and from culture supernatants of normal and transformed fibroblasts. Studies with domain-specific antibodies, J Biol Chem 260, 5105-5114.
91. Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., and Zardi, L. (1994) The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis, Int J Cancer 59, 612-618.
92. Carnemolla, B., Borsi, L., Bannikov, G., Troyanovsky, S., and Zardi, L. (1992) Comparison of human tenascin expression in normal, simian-virus-40-transformed and tumor-derived cell lines, Eur J Biochem 205, 561-567.
93. Borsi, L., Carnemolla, B., Nicolo, G., Spina, B., Tanara, G., and Zardi, L. (1992) Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues, Int J Cancer 52, 688-692.
94. Brack, S. S., Dinkelborg, L. M., and Neri, D. (2004) Molecular targeting of angiogenesis for imaging and therapy, Eur J Nucl Med Mol Imaging 31, 1327-1341.
95. Ebbinghaus, C., Scheuermann, J., Neri, D., and Elia, G. (2004) Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis, Curr Pharm Des 10, 1537-1549.
96. Alessi, P., Ebbinghaus, C., and Neri, D. (2004) Molecular targeting of angiogenesis, Biochim Biophys Acta 1654, 39-49.
97. Wang, J. M., Kumar, S., Pye, D., van Agthoven, A. J., Krupinski, J., and Hunter, R.D. (1993) A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues, Int J Cancer 54, 363-370.
98. Burrows, F. J., Derbyshire, E. J., Tazzari, P. L., Amlot, P., Gazdar, A. F., King, S.W., Letarte, M., Vitetta, E. S., and Thorpe, P. E. (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy, Clin Cancer Res 1, 1623-1634.
99. Brekken, R. A., Huang, X., King, S.W., and Thorpe, P. E. (1998) Vascular endothelial growth factor as a marker of tumor endothelium, Cancer Res 58, 1952-1959.
100. Oh, P., Li, Y., Yu, J., Durr, E., Krasinska, K. M., Carver, L. A., Testa, J. E., and Schnitzer, J.E. (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy, Nature 429, 629-635.
101. Taniguchi, K., Harada, N., Ohizumi, I., Tsutsumi, Y., Nakagawa, S., Kaiho, S., and Mayumi, T. (2000) Recognition of human activated CD44 by tumor vasculature-targeted antibody, Biochem Biophys Res Commun 269, 671-675.
102. Ran, S., Downes, A., and Thorpe, P. E. (2002) Increased exposure of anionic phospholipids on the surface of tumor blood vessels, Cancer Res 62, 6132-6140.
103. Huminiecki, L., Gorn, M., Suchting, S., Poulsom, R., and Bicknell, R. (2002) Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis, Genomics 79, 547-552.
104. Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R. A., Shapiro, L. H., Arap, W., and Ruoslahti, E. (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis, Cancer Res 60, 722-727.
105. St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., and Kinzler, K. W. (2000) Genes expressed in human tumor endothelium, Science 289, 1197-1202.
106. Rybak, J. N., Scheurer, S. B., Neri, D., and Elia, G. (2004) Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution, Proteomics 4, 2296-2299.
107. Glass, C. K., and Witztum, J. L. (2001) Atherosclerosis. The road ahead, Cell 104, 503-516.
108. Libby, P. (2002) Inflammation in atherosclerosis, Nature 420, 868-874.
109. Jaffer, F. A., and Weissleder, R. (2004) Seeing within: molecular imaging of the cardiovascular system, Circ Res 94, 433-445.
110. Reddy, V.Y., Zhang, Q.Y., and Weiss, S. J. (1995) Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages, Proc Natl Acad Sci USA 92, 3849-3853.
111. Leake, D.S., and Peters, T. J. (1981) Proteolytic degradation of low density lipoproteins by arterial smooth muscle cells: the role of individual cathepsins, Biochim Biophys Acta 664, 108-116.
112. Galis, Z. S., and Khatri, J. J. (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly, Circ Res 90, 251-262.
113. Chen, J., Tung, C. H., Mahmood, U., Ntziachristos, V., Gyurko, R., Fishman, M.C., Huang, P. L., and Weissleder, R. (2002) In vivo imaging of proteolytic activity in atherosclerosis, Circulation 105, 2766-2771.
114. Weissleder, R., Tung, C. H., Mahmood, U., and Bogdanov, A., Jr. (1999) In vivo imaging of tumors with protease-activated near-infrared fluorescent probes, Nat Biotechnol 17, 375-378.
115. Jaffer, F. A., Tung, C. H., Gerszten, R. E., and Weissleder, R. (2002) In vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe, Arterioscler Thromb Vasc Biol 22, 1929-1935.
116. Bremer, C., Bredow, S., Mahmood, U., Weissleder, R., and Tung, C.H. (2001) Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model, Radiology 221, 523-529.
117. Kooi, M.E., Cappendijk, V. C., Cleutjens, K. B., Kessels, A. G., Kitslaar, P. J., Borgers, M., Frederik, P. M., Daemen, M.J., and van Engelshoven, J.M. (2003) Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging, Circulation 107, 2453-2458.
118. Lindner, J.R. (2002) Detection of inflamed plaques with contrast ultrasound, Am J Cardiol 90, 32L-35L.
119. Demos, S. M., Alkan-Onyuksel, H., Kane, B. J., Ramani, K., Nagaraj, A., Greene, R., Klegerman, M., and McPherson, D.D. (1999) In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement, J Am Coll Cardiol 33, 867-875.
120. Lindner, J. R., Song, J., Christiansen, J., Klibanov, A. L., Xu, F., and Ley, K. (2001) Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin, Circulation 104, 2107-2112.
121. Leong-Poi, H., Christiansen, J., Klibanov, A. L., Kaul, S., and Lindner, J.R. (2003) Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha( v)-integrins, Circulation 107, 455-460.
122. Joseph, S., Olbrich, C., Kirsch, J., Hasbach, M., Briel, A., and Schirner, M. (2004) A realtime in vitro assay for studying functional characteristics of target-specific ultrasound contrast agents, Pharm Res 21, 920-926.
123. Knight, L. C. (2001) Radiolabeled peptide ligands for imaging thrombi and emboli, Nucl Med Biol 28, 515-526.
124. Shattil, S. J., Hoxie, J. A., Cunningham, M., and Brass, L. F. (1985) Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation, J Biol Chem 260, 11107-11114.
125. Taub, R., Gould, R. J., Garsky, V. M., Ciccarone, T. M., Hoxie, J., Friedman, P. A., and Shattil, S. J. (1989) A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen, J Biol Chem 264, 259-265.
126. Lister-James, J., Knight, L. C., Maurer, A. H., Bush, L. R., Moyer, B. R., and Dean, R.T. (1996) Thrombus imaging with a technetium-99m-labeled activated platelet receptorbinding peptide, J Nucl Med 37, 775-781.
127. Shebuski, R. J., Ramjit, D. R., Bencen, G. H., and Polokoff, M.A. (1989) Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans, J Biol Chem 264, 21550-21556.
128. Tung, C. H., Ho, N.H., Zeng, Q., Tang, Y., Jaffer, F. A., Reed, G. L., and Weissleder, R. (2003) Novel factor XIII probes for blood coagulation imaging, Chembiochem 4, 897-899.
129. Jaffer, F. A., Tung, C. H., Houng, A. K., O'Loughin, T., Reed, G.L., Weissleder, R. (2002) MRI of blood coagulation factor XIII activity using a novel peptide derivatized caged iron oxide nanoparticle (F13-CLIO), Mol Imaging, 217-218.
130. Lanza, G. M., Wallace, K. D., Scott, M.J., Cacheris, W. P., Abendschein, D. R., Christy, D.H., Sharkey, A. M., Miller, J. G., Gaffney, P. J., and Wickline, S. A. (1996) A novel sitetargeted ultrasonic contrast agent with broad biomedical application, Circulation 94, 3334-3340.
131. Flacke, S., Fischer, S., Scott, M. J., Fuhrhop, R. J., Allen, J. S., McLean, M., Winter, P., Sicard, G.A., Gaffney, P. J., Wickline, S. A., and Lanza, G.M. (2001) Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques, Circulation 104, 1280-1285.
132. Barrett, J. A., Kolodziej, A. F., Caravan, P. D., Nair, S., Looby, R., Witte, S., Costello, C. R., Meslia, M.A., Drezwecki, L., Cesna, C., Pratt, C., McMurry, T. J., Lauffer, R. B., Yucel, E. K., Zhao, L., Weisskoff, R. M., Carpenter, A. P., Graham, P. B. (2002) EP-1873, a gadolinium (Gd) labeled fibrin specific agent that rapidly detects arterial and venous thrombi with MRI, Circulation, II-120.
133. Taillefer, R. (2001) Radiolabeled peptides in the detection of deep venous thrombosis, Semin Nucl Med 31, 102-123.
134. Petrich, B. G., and Wang, Y. (2004) Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies, Trends Cardiovasc Med 14, 50-55.
135. Martin, S. J., Reutelingsperger, C. P., McGahon, A. J., Rader, J. A., van Schie, R. C., La-Face, D.M., and Green, D.R. (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl, J Exp Med 182, 1545-1556.
136. Hofstra, L., Liem, I. H., Dumont, E. A., Boersma, H.H., van Heerde, W. L., Doevendans, P. A., De Muinck, E., Wellens, H.J., Kemerink, G. J., Reutelingsperger, C. P., and Heidendal, G. A. (2000) Visualisation of cell death in vivo in patients with acute myocardial infarction, Lancet 356, 209-212.
137. Schellenberger, E. A., Bogdanov, A., Jr., Petrovsky, A., Ntziachristos, V., Weissleder, R., and Josephson, L. (2003) Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy, Neoplasia 5, 187-192.
138. Firestein, G. S. (2003) Evolving concepts of rheumatoid arthritis, Nature 423, 356-361.
139. Kinne, R.W., Brauer, R., Stuhlmuller, B., Palombo-Kinne, E., and Burmester, G.R. (2000) Macrophages in rheumatoid arthritis, Arthritis Res 2, 189-202.
140. Paulos, C. M., Turk, M.J., Breur, G. J., and Low, P.S. (2004) Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis, Adv Drug Deliv Rev 56, 1205-1217.
141. Reddy, J. A., Haneline, L. S., Srour, E. F., Antony, A. C., Clapp, D.W., and Low, P.S. (1999) Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells, Blood 93, 3940-3948.
142. Nakashima-Matsushita, N., Homma, T., Yu, S., Matsuda, T., Sunahara, N., Nakamura, T., Tsukano, M., Ratnam, M., and Matsuyama, T. (1999) Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis, Arthritis Rheum 42, 1609-1616.
143. Turk, M.J., Breur, G. J., Widmer, W. R., Paulos, C. M., Xu, L. C., Grote, L. A., and Low, P. S. (2002) Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis, Arthritis Rheum 46, 1947-1955.
144. Fletcher, D. S., Widmer, W. R., Luell, S., Christen, A., Orevillo, C., Shah, S., and Visco, D. (1998) Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats, J Pharmacol Exp Ther 284, 714-721.
145. van Roon, J. A., van Vuuren, A. J., Wijngaarden, S., Jacobs, K. M., Bijlsma, J.W., Lafeber, F. P., Thepen, T., and van de Winkel, J. G. (2003) Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin, Arthritis Rheum 48, 1229-1238.
146. Wunder, A., Tung, C. H., Muller-Ladner, U., Weissleder, R., and Mahmood, U. (2004) In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response, Arthritis Rheum 50, 2459-2465.
147. Creamer, D., Sullivan, D., Bicknell, R., and Barker, J. (2002) Angiogenesis in psoriasis, Angiogenesis 5, 231-236.
148. Kapsoritakis, A., Sfiridaki, A., Maltezos, E., Simopoulos, K., Giatromanolaki, A., Sivridis, E., and Koukourakis, M.I. (2003) Vascular endothelial growth factor in inflammatory bowel disease, Int J Colorectal Dis 18, 418-422.
149. Xia, Y. P., Li, B., Hylton, D., Detmar, M., Yancopoulos, G. D., and Rudge, J. S. (2003) Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis, Blood 102, 161-168.
150. Boyman, O., Hefti, H.P., Conrad, C., Nickoloff, B. J., Suter, M., and Nestle, F. O. (2004) Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha, J Exp Med 199, 731-736.
151. Hoffmann, J. C., Pawlowski, N. N., Kuhl, A. A., Hohne, W., and Zeitz, M. (2002) Animal models of inflammatory bowel disease: an overview, Pathobiology 70, 121-130.
152. Vinjamuri, S., Hall, A.V., Solanki, K. K., Bomanji, J., Siraj, Q., O'Shaughnessy, E., Das, S. S., and Britton, K. E. (1996) Comparison of 99mTc infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection, Lancet 347, 233-235.
153. Lupetti, A., Welling, M.M., Mazzi, U., Nibbering, P. H., and Pauwels, E. K. (2002) Technetium-99m labelled fluconazole and antimicrobial peptides for imaging of Candida albicans and Aspergillus fumigatus infections, Eur J Nucl Med Mol Imaging 29, 674-679.
154. Knight, L. C. (2003) Non-oncologic applications of radiolabeled peptides in nuclear medicine, Q J Nucl Med 47, 279-291.
155. Welling, M.M., Paulusma-Annema, A., Balter, H. S., Pauwels, E. K., and Nibbering, P.H. (2000) Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations, Eur J Nucl Med 27, 292-301.
156. Tani, K., Murphy, W. J., Chertov, O., Salcedo, R., Koh, C.Y., Utsunomiya, I., Funakoshi, S., Asai, O., Herrmann, S. H., Wang, J. M., Kwak, L.W., and Oppenheim, J. J. (2000) Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens, Int Immunol 12, 691-700.
157. Sair, H. I., Doraiswamy, P. M., and Petrella, J. R. (2004) In vivo amyloid imaging in Alzheimer's disease, Neuroradiology 46, 93-104.
158. Klunk, W. E., Debnath, M.L., and Pettegrew, J.W. (1995) Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe, Neurobiol Aging 16, 541-548.
159. Styren, S. D., Hamilton, R. L., Styren, G. C., and Klunk, W. E. (2000) X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology, J Histochem Cytochem 48, 1223-1232.
160. Zhuang, Z. P., Kung, M.P., Hou, C., Plossl, K., Skovronsky, D., Gur, T. L., Trojanowski, J. Q., Lee, V. M., and Kung, H.F. (2001) IBOX(2-(4'-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain, Nucl Med Biol 28, 887-894.
161. Friedland, R. P., Majocha, R. E., Reno, J. M., Lyle, L. R., and Marotta, C. A. (1994) Development of an anti-A beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease, Mol Neurobiol 9, 107-113.
162. Lovat, L. B., O'Brien, A. A., Armstrong, S. F., Madhoo, S., Bulpitt, C. J., Rossor, M. N., Pepys, M.B., and Hawkins, P. N. (1998) Scintigraphy with 123I-serum amyloid P component in Alzheimer disease, Alzheimer Dis Assoc Disord 12, 208-210.
163. Hawkins, P. N., Rossor, M. N., Gallimore, J. R., Miller, B., Moore, E. G., and Pepys, M.B. (1994) Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease, Biochem Biophys Res Commun 201, 722-726.
164. Hawkins, P. N., Tyrell, P., Jones, T., et al. (1991) Metabolic and scintigraphic studies with radiolabeled serum amyloid P component in amyloidosis: applications to cerebral deposits and Alzheimer disease with positron emission tomography, Bull Clin Neurosci, 178-190.
165. Maggio, J. E., Stimson, E. R., Ghilardi, J. R., Allen, C. J., Dahl, C. E., Whitcomb, D.C., Vigna, S. R., Vinters, H.V., Labenski, M.E., and Mantyh, P.W. (1992) Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide, Proc Natl Acad Sci USA 89, 5462-5466.
166. Saito, Y., Buciak, J., Yang, J., and Pardridge, W.M. (1995) Vector-mediated delivery of 125Ilabeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex, Proc Natl Acad Sci USA 92, 10227-10231.
167. Agdeppa, E. D., Kepe, V., Liu, J., Flores-Torres, S., Satyamurthy, N., Petric, A., Cole, G. M., Small, G.W., Huang, S. C., and Barrio, J. R. (2001) Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease, J Neurosci 21, RC189.
168. Barrio, J. R., Huang, S. C., Cole, G., et al. (1999) PET imaging of tangles and plaques in Alzheimer's disease with a highly hydrophobic probe, J Label Comp Pharm, S194-195.
169. Weissmann, C., Enari, M., Klohn, P. C., Rossi, D., and Flechsig, E. (2002) Transmission of prions, Proc Natl Acad Sci USA 99 Suppl 4, 16378-16383.
170. Klunk, W. E., Bacskai, B. J., Mathis, C. A., Kajdasz, S.T., McLellan, M.E., Frosch, M.P., Debnath, M.L., Holt, D.P., Wang, Y., and Hyman, B.T. (2002) Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative, J Neuropathol Exp Neurol 61, 797-805.
171. Gambhir, S.S. (2002) Molecular imaging of cancer with positron emission tomography, Nat Rev Cancer 2, 683-693.
172. Ugur, O., Kothari, P. J., Finn, R. D., Zanzonico, P., Ruan, S., Guenther, I., Maecke, H.R., and Larson, S.M. (2002) Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors, Nucl Med Biol 29, 147-157.
173. Burt, B. M., Humm, J. L., Kooby, D. A., Squire, O.D., Mastorides, S., Larson, S. M., and Fong, Y. (2001) Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer, Neoplasia 3, 189-195.
174. Wu, A. M., Yazaki, P. J., Tsai, S., Nguyen, K., Anderson, A. L., McCarthy, D.W., Welch, M.J., Shively, J. E., Williams, L. E., Raubitschek, A. A., Wong, J.Y., Toyokuni, T., Phelps, M.E., and Gambhir, S.S. (2000) High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment, Proc Natl Acad Sci USA 97, 8495-8500.
175. Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D., and Zardi, L. (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin, Int J Cancer 102, 75-85.
176. Wan, S., Parrish, J. A., Anderson, R. R., and Madden, M. (1981) Transmittance of nonionizing radiation in human tissues, Photochem Photobiol 34, 679-681.
177. Licha, K., Riefke, B., Ebert, B., and Grotzinger, C. (2002) Cyanine dyes as contrast agents in biomedical optical imaging, Acad Radiol 9 Suppl 2, S320-322.
178. Licha, K., Riefke, B., Ntziachristos, V., Becker, A., Chance, B., and Semmler, W. (2000) Hydrophilic cyanine dyes as contrast agents for near-infrared tumor imaging: synthesis, photophysical properties and spectroscopic in vivo characterization, Photochem Photobiol 72, 392-398.
179. Birchler, M., Neri, G., Tarli, L., Halin, C., Viti, F., and Neri, D. (1999) Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers, J Immunol Methods 231, 239-248.
180. Funovics, M.A., Alencar, H., Su, H. S., Khazaie, K., Weissleder, R., and Mahmood, U. (2003) Miniaturized multichannel near infrared endoscope for mouse imaging, Mol Imaging 2, 350-357.
181. Ntziachristos, V., Yodh, A. G., Schnall, M., and Chance, B. (2000) Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement, Proc Natl Acad Sci USA 97, 2767-2772.
182. Payne, G. (2003) Progress in immunoconjugate cancer therapeutics, Cancer Cell 3, 207-212.
183. Michel, R. B., Brechbiel, M.W., and Mattes, M.J. (2003) A comparison of 4 radionuclides conjugated to antibodies for single-cell kill, J Nucl Med 44, 632-640.
184. Mattes, M.J. (2002) Radionuclide-antibody conjugates for single-cell cytotoxicity, Cancer 94, 1215-1223.
185. Pastan, I., Beers, R., and Bera, T. K. (2004) Recombinant immunotoxins in the treatment of cancer, Methods Mol Biol 248, 503-518.
186. Neri, D. (2004) Tumor targeting, CHIMIA 58(10), 723-726.